An Innovative Intervention for OUD Treatment

Status Recruiting

Clinical Trial Summary

The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment. Importantly, medical devices reviewed by the FDA are cleared (based on safety) rather than approved (based on efficacy), which means the BD did not need to demonstrate efficacy before it became commercially available. As a result, the device was not required to have a sham-controlled trial for FDA clearance and there is no active research, to the investigators' knowledge, that specifically addresses the degree to which opioid withdrawal can be treated through neuromodulation. To rigorously evaluate the efficacy of the BD for treating OUD, the investigators will enroll persons with active OUD, not currently receiving medications for OUD. Participants will be recruited and admitted to the Clinical Research Unit (CRU) for a 2-3 week period. During participants' residential stay, participants will be stabilized for 7-11 days on four times daily morphine (30 mg, SC) and undergo a precipitated withdrawal challenge using the opioid antagonist naloxone, approximately >= 4 days of morphine maintenance. This is a standard practice for the investigators' study and allows the investigators to objectively assess dependence. The BD and study medication will begin following morphine stabilization. Participants will be randomly assigned to one of three conditions (1) active BD with placebo (BD/P), (2) sham BD with lofexidine (SBD/L), or (3) sham BD and placebo (SBD/P). Participants will use the BD for 5 days and will receive study drug for 7 days. Participants will be monitored for an additional 4 days after device removal to determine whether withdrawal resumes. Participants will undergo a second naloxone challenge after removal of the device/capsule completion to verify lack of opioid tolerance and will be encouraged to begin treatment with oral naltrexone followed by extended release naltrexone. Throughout the residential stay, all participants will be given referral to and assisted with engaging in outpatient treatment following study discharge.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04325659
Study type	Interventional
Source	Johns Hopkins University
Contact	Cecilia L Bergeria, PhD
Phone	410-550-1979
Email	cberge21@jhmi.edu
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	November 15, 2020
Completion date	October 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03950492` - Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder	N/A
Completed	`NCT00000335` - Activity Monitoring Assessment of Opiate Withdrawal - 4	Phase 2
Active, not recruiting	`NCT03949764` - The Kentucky Viral Hepatitis Treatment Study	Phase 4
Enrolling by invitation	`NCT06084221` - Fatal Overdose Review Teams - Research to Enhance Surveillance Systems	N/A
Completed	`NCT02978417` - Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings	Phase 4
Withdrawn	`NCT03137017` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults	Phase 1
Withdrawn	`NCT03137030` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults	Phase 1
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT00710385` - Abuse Liability of Suboxone Versus Subutex	Phase 3
Completed	`NCT00142935` - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1	N/A
Completed	`NCT00218309` - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals	Phase 2
Completed	`NCT00067184` - Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Terminated	`NCT00000243` - Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone	N/A
Completed	`NCT00000264` - Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16	N/A
Completed	`NCT00000257` - Effects of Alcohol History on Effects of Nitrous Oxide - 9	N/A
Completed	`NCT00000306` - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3	Phase 2
Completed	`NCT00000279` - Novel Medications for Opiate Detoxification - 4	Phase 2
Completed	`NCT00000249` - Effects of Subanesthetic Concentrations of Nitrous Oxide - 1	Phase 2
Recruiting	`NCT04933084` - Pre-operative Education Modalities to Decrease Opioid Use	N/A
Recruiting	`NCT03610672` - Mobile Intervention for Young Opioid Users	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

An Innovative Intervention for OUD Treatment — Bridge

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms